{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:27:47Z","timestamp":1793262467188,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.eclinm.2023.102258","type":"journal-article","created":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T13:28:01Z","timestamp":1696253281000},"page":"102258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5105-8427","authenticated-orcid":false,"given":"Ravi","family":"Savarirayan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G.","family":"Hoernschemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merete","family":"Ljungberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri A.","family":"Zarate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Bacino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Bober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet M.","family":"Legare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"H\u00f6gler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Quattrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Jennifer","family":"Abuzzahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klane K.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina S.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schnabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9rgio B.","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alden","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukta","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adebola","family":"Giwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bent","family":"Winding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte","family":"Volck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee D.","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9414-5873","authenticated-orcid":false,"given":"Ciara","family":"McDonnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.eclinm.2023.102258_bib1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41574-021-00595-x","article-title":"International consensus statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia","volume":"18","author":"Savarirayan","year":"2022","journal-title":"Nat Rev Endocrinol"},{"issue":"9582","key":"10.1016\/j.eclinm.2023.102258_bib2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0140-6736(07)61090-3","article-title":"Achondroplasia","volume":"370","author":"Horton","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102258_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.berh.2007.12.008","article-title":"Achondroplasia","volume":"22","author":"Baujat","year":"2008","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.eclinm.2023.102258_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.115872","article-title":"Lifetime impact of achondroplasia: current evidence and perspectives on the natural history","volume":"146","author":"Hoover-Fong","year":"2021","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102258_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-018-0972-6","article-title":"Achondroplasia: a comprehensive clinical review","volume":"14","author":"Pauli","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102258_bib6","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0092-8674(00)81069-7","article-title":"Fibroblast growth factor receptor 3 is a negative regulator of bone growth","volume":"84","author":"Deng","year":"1996","journal-title":"Cell"},{"issue":"6494","key":"10.1016\/j.eclinm.2023.102258_bib7","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/371252a0","article-title":"Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia","volume":"371","author":"Rousseau","year":"1994","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102258_bib8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0092-8674(94)90302-6","article-title":"Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia","volume":"78","author":"Shiang","year":"1994","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.eclinm.2023.102258_bib9","doi-asserted-by":"crossref","first-page":"5916","DOI":"10.3390\/ijms23115916","article-title":"Molecular mechanism of induction of bone growth by the C-type natriuretic peptide","volume":"23","author":"Rintz","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102258_bib10","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nm971","article-title":"Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway","volume":"10","author":"Yasoda","year":"2004","journal-title":"Nat Med"},{"issue":"9-10","key":"10.1016\/j.eclinm.2023.102258_bib11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1159\/000520812","article-title":"Evolution and future of growth plate therapeutics","volume":"94","author":"Allen","year":"2021","journal-title":"Horm Res Paediatr"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102258_bib12","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.ajhg.2012.10.014","article-title":"Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia","volume":"91","author":"Lorget","year":"2012","journal-title":"Am J Hum Genet"},{"issue":"10252","key":"10.1016\/j.eclinm.2023.102258_bib13","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0140-6736(20)31541-5","article-title":"Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial","volume":"396","author":"Savarirayan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2023.102258_bib14","series-title":"Voxzogo (vosoritide) [package insert]","year":"2021"},{"key":"10.1016\/j.eclinm.2023.102258_bib15","series-title":"Voxzogo (vosoritide) [package insert]","year":"2022"},{"key":"10.1016\/j.eclinm.2023.102258_bib16","series-title":"Voxzogo (vosoritide) [package insert]","year":"2021"},{"key":"10.1016\/j.eclinm.2023.102258_bib17","series-title":"Voxzogo (vosoritide) [package insert]","year":"2022"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102258_bib18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1124\/jpet.119.258251","article-title":"TransCon CNP, a sustained-release C-type natriuretic peptide prodrug, a potentially safe and efficacious new therapeutic modality for the treatment of comorbidities associated with fibroblast growth factor receptor 3\u2013related skeletal dysplasias","volume":"370","author":"Breinholt","year":"2019","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"11","key":"10.1016\/j.eclinm.2023.102258_bib19","doi-asserted-by":"crossref","first-page":"4763","DOI":"10.1111\/bcp.15369","article-title":"Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamics results of a long-acting C-type natriuretic peptide prodrug, TransCon CNP","volume":"88","author":"Breinholt","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102258_bib20","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1186\/s13023-021-02141-4","article-title":"Growth in achondroplasia including stature, weight, weight-for-height and head circumference from CLARITY: achondroplasia natural history study\u2014a multi-center retrospective cohort study of achondroplasia in the US","volume":"16","author":"Hoover-Fong","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.eclinm.2023.102258_bib22","series-title":"Minutes of a joint meeting of the pediatric advisory committee and the endocrinologic and metabolic drugs advisory committee","year":"2018"},{"issue":"219","key":"10.1016\/j.eclinm.2023.102258_bib23","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1136\/adc.41.219.454","article-title":"Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. I","volume":"41","author":"Tanner","year":"1966","journal-title":"Arch Dis Child"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102258_bib24","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1515\/jpem-2020-0298","article-title":"Growth in achondroplasia, from birth to adulthood, analysed by the JPA-2 model","volume":"33","author":"Del Pino","year":"2020","journal-title":"J\u00a0Pediatr Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102258_bib25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1056\/NEJMoa1813446","article-title":"C-type natriuretic peptide analogue therapy in children with achondroplasia","volume":"381","author":"Savarirayan","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2023.102258_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221084848","article-title":"Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies","volume":"14","author":"Savarirayan","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102258_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0244368","article-title":"In\u00a0vitro and in\u00a0vivo characterization of recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia","volume":"15","author":"Goncalves","year":"2020","journal-title":"PLoS One"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023004352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023004352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:23:35Z","timestamp":1762899815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537023004352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":26,"alternative-id":["S2589537023004352"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102258","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102258","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102258"}}